ArticleEuropean journal of medical research2025
The machine learning methods aid to choose ezetimibe or statins for ischemic stroke patients with SLCO1B1 variants.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundStatins had a higher risk of statin-induced side effects for acute ischemic stroke patients with SLCO1B1 variants. Ezetimibe might reach the low-density lipoprotein cholesterol (LDL-C) level to recommend a range with a low risk of side effects. Which effect was better needs validation?
methodsData from acute ischemic stroke patients with SLCO1B1 variants administered. The stroke recurrence within 1 year and recommended LDL-C level 30 days after admission were used to evaluate the primary outcome. The secondary outcome included unfavorable functional outcomes and side effects of statins.
resultsThe mean age of the 158 patients was 66.59 ± 13.268 years, and 65 were female (41.1%). The ezetimibe group had a lower stroke recurrence (6.3% vs. 17.9%, p = 0.036), a higher rate of patients reaching the recommended LDL-C level (81.0% vs. 48.4%, p < 0.001), and a lower rate of side effects of statins (3.2% vs. 13.7%, p = 0.027). Regression analysis showed the ezetimibe was related to stroke recurrence (OR = 0.276, p = 0.039), the recommended LDL-C level (OR = 2.312, p < 0.001), and side effects of statins (OR = 0.194, p = 0.038), but not to unfavorable functional outcomes at 90 days after admission (OR = 0.960, p = 0.911). The patients had a significant difference in base character and outcome events between the hierarchical clustering groups.
conclusionsThe ezetimibe group had a lower rate of recurrence and side effects, a higher rate of recommended LDL-C level, and a similar unfavorable functional outcome. For male, younger stroke patients with SLCO1B1 variants, higher blood pressure, and blood lipid using ezetimibe are related to a better prognosis than other patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.